TELA Bio, Inc. (TELA)
NASDAQ: TELA · Real-Time Price · USD
1.850
-0.010 (-0.54%)
Aug 4, 2025, 4:00 PM - Market closed
Marathon Oil Revenue
TELA Bio had revenue of $18.52M in the quarter ending March 31, 2025, with 11.55% growth. This brings the company's revenue in the last twelve months to $71.22M, up 12.78% year-over-year. In the year 2024, TELA Bio had annual revenue of $69.30M with 18.56% growth.
Revenue (ttm)
$71.22M
Revenue Growth
+12.78%
P/S Ratio
0.88
Revenue / Employee
$340,751
Employees
209
Market Cap
73.18M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 69.30M | 10.85M | 18.56% |
Dec 31, 2023 | 58.45M | 17.04M | 41.13% |
Dec 31, 2022 | 41.42M | 11.96M | 40.58% |
Dec 31, 2021 | 29.46M | 11.25M | 61.77% |
Dec 31, 2020 | 18.21M | 2.77M | 17.91% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TELA News
- 12 days ago - TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 14 days ago - TELA Bio to Announce Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair - GlobeNewsWire
- 2 months ago - TELA Bio Appoints Jeffrey Blizard as President - GlobeNewsWire
- 2 months ago - TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - TELA Bio, Inc. (TELA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire